ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
Transcriptome analysis of distinct long non-coding RNA transcriptional fingerprints in lung adenocarcinoma and squamous cell carcinoma.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Long non‑coding RNA HOTTIP promotes hepatocellular carcinoma tumorigenesis and development: A comprehensive investigation based on bioinformatics, qRT‑PCR and meta‑analysis of 393 cases.International journal of oncology · 2017Pooled it
- Comprehensive insights and In silico analysis into the emerging role of LincRNAs in lung diseases pathogenesis; a step toward ncRNA precision.Functional & integrative genomics · 2025Review
- Analysis and exploration of regulatory mechanisms and potential prognostic biomarkers in squamous cell carcinoma of the lung by expression profiling.Translational cancer research · 2025Article
- Identification of tumor-suppressor genes in lung squamous cell carcinoma through integrated bioinformatics analyses.Oncology research · 2023Article
- LINC00511 aggravates the malignancy of lung adenocarcinoma through sponging microRNA miR-4739 to regulate pyrroline-5-carboxylate reductase 1 expression.Journal of clinical laboratory analysis · 2022Article
- Analysis of anti-apoptotic PVT1 oncogene and apoptosis-related proteins (p53, Bcl2, PD-1, and PD-L1) expression in thyroid carcinoma.Journal of clinical laboratory analysis · 2022Article
- Article
- A two-phase comprehensive NSCLC prognostic study identifies lncRNAs with significant main effect and interaction.Molecular genetics and genomics : MGG · 2022Article
- A Review on the Role of AFAP1-AS1 in the Pathoetiology of Cancer.Frontiers in oncology · 2021Review
- Microarray profiling of differentially expressed lncRNAs and mRNAs in lung adenocarcinomas and bioinformatics analysis.Cancer medicine · 2020Article
- Long Noncoding MAGI2-AS3 Suppresses Several Cellular Processes of Lung Squamous Cell Carcinoma Cells by Regulating miR-374a/b-5p/CADM2 Axis.Cancer management and research · 2020Article
- Identification of Potential Long Non-coding RNA Expression Quantitative Trait Methylations in Lung Adenocarcinoma and Lung Squamous Carcinoma.Frontiers in genetics · 2020Article
- LINC00511 is associated with the malignant status and promotes cell proliferation and motility in cervical cancer.Bioscience reports · 2019Article
- LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel.Journal of biosciences · 2019Article
- Genomewide identification of a novel six-LncRNA signature to improve prognosis prediction in resectable hepatocellular carcinoma.Cancer medicine · 2018Article
- LncRNA AFAP1-AS1 is a prognostic biomarker and serves as oncogenic role in retinoblastoma.Bioscience reports · 2018Article
- Survival prediction of kidney renal papillary cell carcinoma by comprehensive LncRNA characterization.Oncotarget · 2017Article
- Clinical roles of the aberrantly expressed lncRNAs in lung squamous cell carcinoma: a study based on RNA-sequencing and microarray data mining.Oncotarget · 2017Article
- Identification of a RNA-Seq based prognostic signature with five lncRNAs for lung squamous cell carcinoma.Oncotarget · 2017Article
- Genome-Wide Analysis of mRNA and Long Noncoding RNA Profiles in Chronic Actinic Dermatitis.BioMed research international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related death, including two major pathologic subtypes, adenocarcinoma (AD) and squamous cell carcinoma (SCC). There are significant differences in the aberrant gene profiling and molecular characteristics among LUAD and LUSC, which lead to the different chemotherapeutic regimens administered to the two NSCLC subtypes. Therefore, unique genetic or epigenetic accurately distinguishing these two subtypes is critical for the diagnosis and treatment of patients. In this study, we tried to develop and validate novel long non-coding RNA (lncRNA)-based signatures to facilitate the diagnosis and individualized treatment of LUAD and LUSC. To analyze the distinct lncRNA profiling in LUAD and LUSC, the paired tissue samples of RNA sequencing or microarray data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) was used. We found that lncRNA expression pattern is different in LUAD and LUSC, and three up-regulated and down-regulated lncRNAs expressions in LUAD and LUSC tissues were validated. In addition, knockdown of the up-regulated lncRNA AFAP1-AS1 and LINC00511 impaired LUAD cell proliferation, while knockdown of PVT1 inhibited LUSC cell growth. Furthermore, four 6-lncRNAs signature expression patterns were found to be significantly associated with LUAD and LUSC patient overall and progression-free survival. Taken together, the different lncRNAs signature might accurately distinguish LUAD and LUSC and predict clinical outcome for these two different subtypes of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.